PDF(Pubmed)
Abstract：
UNASSIGNED: Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are the two main pathological types of esophageal cancer (EC), which differ in molecular features, genetic variation, and treatment sensitivity. However, as a key process in tumorigenesis and development, the role of N6-methyladenosine (m6A) regulators in esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) is not fully understood.
UNASSIGNED: This study systematically compared the role of m6A regulators of ESCC and EAC in terms of molecular characteristics, immuno-oncology characteristics, and clinical relevance, and validated our findings in a long-term follow-up patient cohort.
UNASSIGNED: There were many differences in m6A regulators between ESCC and EAC in terms of expression patterns, genetic variation, association with tumor pathways, immune signatures, and immunotherapy sensitivity. Furthermore, VIRMA was identified as a factor with opposite functional and prognostic effects in ESCC and EAC. ESCC patients with high VIRMA expression and EAC patients with low VIRMA expression had a better prognosis. Single-center data showed that low expression of FTO may be associated with superior immunotherapy efficacy in ESCC patients.
UNASSIGNED: The results herein provide novel ideas for understanding the tumor characteristics, occurrence, and development of ESCC and EAC, and suggest new targets for the treatment and intervention of EC.
UNASSIGNED: This study systematically compared the role of m6A regulators of ESCC and EAC in terms of molecular characteristics, immuno-oncology characteristics, and clinical relevance, and validated our findings in a long-term follow-up patient cohort.
UNASSIGNED: There were many differences in m6A regulators between ESCC and EAC in terms of expression patterns, genetic variation, association with tumor pathways, immune signatures, and immunotherapy sensitivity. Furthermore, VIRMA was identified as a factor with opposite functional and prognostic effects in ESCC and EAC. ESCC patients with high VIRMA expression and EAC patients with low VIRMA expression had a better prognosis. Single-center data showed that low expression of FTO may be associated with superior immunotherapy efficacy in ESCC patients.
UNASSIGNED: The results herein provide novel ideas for understanding the tumor characteristics, occurrence, and development of ESCC and EAC, and suggest new targets for the treatment and intervention of EC.
摘要：
UNASSIGNED：鳞状细胞癌（SCC）和腺癌（AC）是食管癌（EC）的两种主要病理类型，分子特征不同，遗传变异，和治疗敏感性。然而,作为肿瘤发生和发展的关键过程，N6-甲基腺苷(m6A)调节因子在食管鳞状细胞癌(ESCC)和食管腺癌(EAC)中的作用尚不完全清楚.
UNASSIGNED：本研究系统地比较了ESCC和EAC的m6A调节剂在分子特征方面的作用，免疫肿瘤学特征，和临床相关性，并在长期随访患者队列中验证了我们的发现。
UNASSIGNED：在表达模式方面，ESCC和EAC之间的m6A调节因子存在许多差异，遗传变异，与肿瘤通路相关，免疫特征，和免疫疗法的敏感性。此外，VIRMA被确定为在ESCC和EAC中具有相反的功能和预后影响的因素。VIRMA高表达的ESCC患者和VIRMA低表达的EAC患者预后较好。单中心数据显示，在ESCC患者中，FTO的低表达可能与较好的免疫治疗效果相关。
UASSIGNED：本文的结果为理解肿瘤特征提供了新的思路，发生,以及ESCC和EAC的发展，并提出新的治疗和干预措施的目标。
UNASSIGNED：本研究系统地比较了ESCC和EAC的m6A调节剂在分子特征方面的作用，免疫肿瘤学特征，和临床相关性，并在长期随访患者队列中验证了我们的发现。
UNASSIGNED：在表达模式方面，ESCC和EAC之间的m6A调节因子存在许多差异，遗传变异，与肿瘤通路相关，免疫特征，和免疫疗法的敏感性。此外，VIRMA被确定为在ESCC和EAC中具有相反的功能和预后影响的因素。VIRMA高表达的ESCC患者和VIRMA低表达的EAC患者预后较好。单中心数据显示，在ESCC患者中，FTO的低表达可能与较好的免疫治疗效果相关。
UASSIGNED：本文的结果为理解肿瘤特征提供了新的思路，发生,以及ESCC和EAC的发展，并提出新的治疗和干预措施的目标。
